Substance / Medication

Amoxapine

Overview

Active Ingredient
amoxapine
RxNorm CUI
722

Indications

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Labeler: Chartwell RX, LLCUpdated: 2024-12-18T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of amoxapine or any other antidepress

Contraindications

When this intervention should not be used

Amoxapine is contraindicated in patients who have shown prior hypersensitivity to dibenzoxazepine compounds. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressants and m

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry Imran B, Husain Nusrat, Khan Salahuddin et al. · J Clin Psychopharmacol · 2007
PMID: 18004123Observational
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
Apiquian Rogelio, Fresan Ana, Ulloa Rosa-Elena et al. · Neuropsychopharmacology · 2005
PMID: 15956984Observational
Successful Treatment of Amoxapine-Induced Intractable Seizures With Intravenous Lipid Emulsion.
Matsuoka Masaru, Imai Toru, Iwabuchi Sou et al. · J Emerg Med · 2023
PMID: 36450616Case Report
Refractory hypotension during general anaesthesia caused by the long-term use of amoxapine.
Takechi K, Abe T, Yorozuya T et al. · Anaesth Intensive Care · 2010
PMID: 20865899Case Report
Amoxapine-associated acute respiratory distress.
Ando Masaru, Miyazaki Eishi, Takenaka Ryu-Ichi et al. · Respirology · 2008
PMID: 18197927Case Report
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs.
Kudo Keiko, Inoue Hiromasa, Ishida Tomomi et al. · Leg Med (Tokyo) · 2007
PMID: 17150394Case Report
Amoxapine treatment of interfering behaviors in autistic disorder.
Craven-Thuss Beth, Nicolson Rob · J Am Acad Child Adolesc Psychiatry · 2003
PMID: 12707553Case Report
Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult.
Gupta S, Racaniello A A · Ann Clin Psychiatry · 2000
PMID: 10907803Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amoxapine (substance)
SNOMED CT
373754002
UMLS CUI
C0002644
RxNorm CUI
722
Labeler
Chartwell RX, LLC

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.